journal article·2023-06-07

Glutathione Depleting a Chemoselective Novel Pro-oxidant Nano Metal–Organic Framework Induced G2/M Arrest and ROS-Mediated Apoptotic Cell Death in a Human Triple-Negative Breast Cancer Cell Line

Suhana Karim, Satyajit Halder, Somali Mukherjee, Utsab Debnath, Anup Kumar Misra, Kuladip Jana, Debasis Das

ACS Applied Materials & Interfaces· Volume 15· Issue 22
Publisher page

Abstract

The progression of a new class of compounds to inhibit the uncontrolled proliferation of carcinoma cells has become one of the most powerful weapons to combat “cancer”. To this end, a new Mn(II)-based metal–organic framework, namely, [{Mn(5N 3 -IPA)(3-pmh)}(H 2 O)] α (5N 3 H 2 -IPA = 5-azidoisophthalic acid and 3-pmh = (3-pyridylmethylene)hydrazone), has been synthesized adopting a mixed ligand approach and exploited as a successful anticancer agent via systematic in vitro and in vivo studies. Single-crystal X-ray diffraction analyses depict that MOF 1 exhibits a 2D pillar-layer structure consisting of water molecules in each 2D void space. Due to the insolubility of the as-synthesized MOF 1, a green hand grinding methodology has been adopted to scale down the particle size to the nanoregime keeping its structural integrity intact. The nanoscale metal–organic framework ( NMOF 1 ) adopts a discrete spherical morphology as affirmed by scanning electron microscopic analysis. The photoluminescence studies revealed that NMOF 1 is highly luminescent, enhancing its biomedical proficiency. Initially, the affinity of the synthesized NMOF 1 for GSH-reduced has been evaluated by various physicochemical techniques. NMOF 1 constrains the proliferation of cancer cells in vitro by inducing G2/M seizure and accordingly leads to apoptotic cell death. More significantly, compared to cancer cells, NMOF 1 exhibits less cytotoxicity against normal cells. It has been demonstrated that NMOF 1 interacts with GSH, causing a drop in cellular GSH levels and the production of intercellular ROS. It is quite intriguing that we discovered that NMOF 1 -mediated ROS generation aids in significantly modifying the mitochondrial redox status, which is a crucial factor in apoptosis. According to mechanistic research, NMOF 1 increases the production of proapoptotic proteins and lowers the expression of antiapoptotic proteins, which significantly aids in activating caspase 3 and the subsequent cleavage of PARP1 and cell death via intrinsic apoptotic pathways. Finally, an in vivo investigation using immuno-competent syngeneic mice demonstrates that NMOF 1 can stop tumor growth without causing adverse side effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, University College of Science, University of Calcutta, 92 A. P. C. Road, Kolkata 700009, India

Division of Molecular Medicine, Bose Institute, Unified Academic Campus, EN 80, Sector V, Bidhan Nagar, Kolkata 700091, WB, India

Department of Chemistry, Scottish Church College, 1 & 3, Urquhart Square, Kolkata 700006, India

School of Health Sciences and Technology, University of Petroleum and Energy Studies, Dehradun 248007, India

Funding

University Grants Commission · Department of Science and Technology, Ministry of Science and Technology, India

References (61)

Show source-provided references
1. 10.1016/j.bjbas.2015.05.00410.1016/j.bjbas.2015.05.004 ↗
2. 10.1016/j.cej.2020.12789910.1016/j.cej.2020.127899 ↗
3. 10.1016/j.jinorgbio.2015.08.01610.1016/j.jinorgbio.2015.08.016 ↗
4. 10.1002/adma.20190151310.1002/adma.201901513 ↗
5. 10.1615/CritRevBiomedEng.v40.i1.2010.1615/CritRevBiomedEng.v40.i1.20 ↗
6. 10.1038/nature0773310.1038/nature07733 ↗
7. 10.1021/acsnano.9b0030010.1021/acsnano.9b00300 ↗
8. 10.1021/acsnano.8b0118610.1021/acsnano.8b01186 ↗
9. 10.1038/nrc189410.1038/nrc1894 ↗
10. 10.1016/j.ica.2017.05.03510.1016/j.ica.2017.05.035 ↗
11. 10.1002/ardp.20060015110.1002/ardp.200600151 ↗
12. 10.1038/natrevmats.2015.1810.1038/natrevmats.2015.18 ↗
13. 10.1016/j.ccr.2019.02.02210.1016/j.ccr.2019.02.022 ↗
14. 10.1021/acs.chemrev.6b0034610.1021/acs.chemrev.6b00346 ↗
15. 10.1021/cr200314710.1021/cr2003147 ↗
16. 10.1039/b807080f10.1039/b807080f ↗
17. 10.1021/acssuschemeng.2c0454310.1021/acssuschemeng.2c04543 ↗
18. 10.1002/anie.20170723810.1002/anie.201707238 ↗
19. 10.1021/ja512311a10.1021/ja512311a ↗
20. 10.1002/anie.20100043110.1002/anie.201000431 ↗
21. 10.1002/anie.20131053610.1002/anie.201310536 ↗
22. 10.1016/j.ccr.2013.01.00510.1016/j.ccr.2013.01.005 ↗
23. 10.1039/C7CS00162B10.1039/C7CS00162B ↗
24. 10.1021/acs.accounts.0c0026810.1021/acs.accounts.0c00268 ↗
25. 10.1021/cr200256v10.1021/cr200256v ↗
26. 10.1016/j.jcis.2022.04.07810.1016/j.jcis.2022.04.078 ↗
27. 10.2174/092986732566618021412350010.2174/0929867325666180214123500 ↗
28. 10.1021/cr200225710.1021/cr2002257 ↗
29. 10.1039/C7GC01078H10.1039/C7GC01078H ↗
30. 10.1039/D0BM01328E10.1039/D0BM01328E ↗
31. 10.1021/ja803383k10.1021/ja803383k ↗
32. 10.1021/ja062744410.1021/ja0627444 ↗
33. 10.1002/anie.20080291110.1002/anie.200802911 ↗
34. 10.1038/nmat260810.1038/nmat2608 ↗
35. 10.1002/chem.20090238210.1002/chem.200902382 ↗
36. 10.1002/chem.20160460410.1002/chem.201604604 ↗
37. 10.1021/acs.inorgchem.8b0023710.1021/acs.inorgchem.8b00237 ↗
38. 10.1038/s41419-018-0476-210.1038/s41419-018-0476-2 ↗
39. 10.1021/acsami.9b0262210.1021/acsami.9b02622 ↗
40. 10.1016/j.ijhydene.2022.08.00610.1016/j.ijhydene.2022.08.006 ↗
41. 10.1016/S0300-483X(02)00073-210.1016/S0300-483X(02)00073-2 ↗
42. 10.1039/D2NJ03308A10.1039/D2NJ03308A ↗
43. 10.3390/ijms2304215010.3390/ijms23042150 ↗
44. Bruker · 2012
45. Bruker · 2001
46. 10.1107/S002188980804272610.1107/S0021889808042726 ↗
47. 10.1038/bjc.1987.19010.1038/bjc.1987.190 ↗
48. 10.1016/j.jconrel.2023.01.02410.1016/j.jconrel.2023.01.024 ↗
49. 10.1002/0471142735.ima03bs2110.1002/0471142735.ima03bs21 ↗
50. 10.1002/0471142956.cy0902s6410.1002/0471142956.cy0902s64 ↗
51. 10.1385/1-59259-406-910.1385/1-59259-406-9 ↗
52. 10.1039/C7RA04207H10.1039/C7RA04207H ↗
53. 10.15171/bi.2015.0110.15171/bi.2015.01 ↗
54. 10.1385/MB:26:3:24910.1385/MB:26:3:249 ↗
55. 10.1007/978-1-60761-411-1_410.1007/978-1-60761-411-1_4 ↗
56. 10.1016/j.bmcl.2014.06.05410.1016/j.bmcl.2014.06.054 ↗
57. 10.3389/fphar.2016.0011410.3389/fphar.2016.00114 ↗
58. 10.1021/bi980650410.1021/bi9806504 ↗
59. 2006
60. 10.1007/s10822-013-9667-110.1007/s10822-013-9667-1 ↗
61. 2017